ArticleBlood research2026
Clinical heterogeneity of primary cutaneous γδ T-cell lymphoma: a 20-year single-institution experience.
Article in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary cutaneous γδ T-cell lymphoma (PCGDTCL) is a rare cutaneous T-cell lymphoma defined by γδ T-cell receptor expression and a cytotoxic phenotype. It has historically been considered highly aggressive, with median survival of 15-30 months and no standardized treatment due to its rarity. However, emerging reports describe subsets with relatively indolent behavior. We report a 20-year single-institution experience to better define the clinical spectrum and therapeutic implications of PCGDTCL.
methodsPatients diagnosed with PCGDTCL at Samsung Medical Center between January 2005 and September 2025 were retrospectively reviewed. Clinical, pathologic, and immunophenotypic features were collected and confirmed by hematopathology review. Pathologic features were visualized using heatmaps, and treatment courses were visualized using swimmer plots. Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
resultsSix patients were identified (median age 57 years). All presented with cutaneous lesions, ranging from localized solitary lesions to multifocal cutaneous involvement. ^18F-fluorodeoxyglucose positron emission tomography (FDG-PET) demonstrated heterogeneous metabolic activity, with maximum standardized uptake values (SUVmax) ranging from absent uptake to 8.9. Immunophenotyping showed uniform CD3 positivity, T-cell receptor γδ expression, βF1 negativity, and variable CD4, CD8, and CD56 expression. First-line therapies included observation, corticosteroids, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and GDP (gemcitabine, dexamethasone, cisplatin). Durable complete remissions occurred with CHOP and GDP. One patient experienced multiple relapses, later developed clinicopathologic features resembling mycosis fungoides, and survived for 13 years.
conclusionPCGDTCL appears to show broader clinical and therapeutic heterogeneity than historically appreciated. Durable responses in selected patients suggest that treatment responsiveness may vary across the disease spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.